AR042634A1 - Compuestos de aminobenzofenona - Google Patents

Compuestos de aminobenzofenona

Info

Publication number
AR042634A1
AR042634A1 ARP030104756A ARP030104756A AR042634A1 AR 042634 A1 AR042634 A1 AR 042634A1 AR P030104756 A ARP030104756 A AR P030104756A AR P030104756 A ARP030104756 A AR P030104756A AR 042634 A1 AR042634 A1 AR 042634A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
olefinic
hydroxy
heterocyclyl
Prior art date
Application number
ARP030104756A
Other languages
English (en)
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of AR042634A1 publication Critical patent/AR042634A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente compuesto de fórmula (1), siendo dichos compuestos útiles, en el tratamiento de enfermedades inflamatorias. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), donde R1 representa un sustituyente seleccionado entre el grupo que consiste en halógeno, hidroxi, mercapto, trifluorometilo, amino, alquilo (C1-3), grupo olefínico (C2-3), alcoxi (C1-3), alquiltio (C1-3), alquilamino (C14) y ciano; R2 representa uno o más sustituyentes, iguales o diferentes, seleccionados entre el grupo que consiste en hidrógeno, halógeno, hidroxi, mercapto, trifluorometilo, amino, alquilo (C1-3), grupo olefínico (C2-3), alcoxi (C1-3), alquiltio (C1-3), alquilamino (C1-4), alcoxicarbonilo (C1-3), ciano y nitro; R3 representa uno o más sustituyentes, iguales o diferentes, seleccionados entre el grupo que consiste en hidrógeno, halógeno, hidroxi, mercapto, trifluorometilo, ciano, carboxi, carbamoílo, alquilo (C1-4), grupo olefínico (C2-4), alcoxi (C1-4), alquiltio (C1-4) y alcoxicarbonilo (C1-4); R4 representa uno o más sustituyentes, iguales o diferentes, seleccionados entre el grupo que consiste en hidrógeno, halógeno, hidroxi, mercapto, trifluorometilo, amino, alquilo (C1-3), grupo olefínico (C2-3), alcoxi (C1-3), alquiltio (C1-3), alquilamino (C1-4), alcoxicarbonilo (C1-3), ciano y nitro; R5 representa hidrógeno, alquilo C1-6) y grupo olefínico (C2-6); R6 representa hidrógeno, alquilo (C1-6) y grupo olefínico (C2-6); R7 representa alquilo (C1-18), grupo hidrocarburos cíclicos (C3-8), grupo olefínico, (C2-18), heterociclilo, alquinilo (C2-18), alquil(C1-18)-heterociclilo, alquil(C1-18)-grupo hidrocarburos cíclicos(C3-8), grupo olefínico(C2-18)-heterociclilo, grupo olefínico(C2-18)-grupo de hidrocarburos cíclicos(C3-8), alquinil(C2-18)-heterociclilo, alquinilo(C2-18)-grupo de hidrocarburos cíclicos(C3-8); y donde R7 puede ser opcionalmente sustituido con uno o más sustituyentes representados por R8; R8 representa halógeno, hidroxi, mercapto, trifluorometilo, amino, alquilo (C1-6), alcoxi (C1-6), alquiltio (C1-6), alquilamino (C1-6), alcoxicarbonilo (C1-6), trialquilamonio (C1-9) en asociación con un anión farmacéuticamente aceptable, dialquilfosfinoilo (C2-12), alquil(C1-6)(hidroxi)fosfinoilo, dialquilfosfinoiloxi (C2-12), alquil(C1-6)(hidroxi)fosfinoiloxi, dihidroxifosfinoilo, dihidroxifosfinoiloxi, ciano, azido, nitro, -CHO, -COOH, -CONH2, -CONNHR', -CONRR' donde R y R' representan alquilo C1-3) o Y-R9; Y representa -O-, -S-, -S(O)-, -S(O)2-, -NRa-, -NRaC(O)NRb-, -NRaC(O)-, -C(O)NRa-, -C(O)-, -C(O)O-, -OC(O)-, -NRaC(O)O-, -OC(O)NRa-, -S(O)2NRa-, -NRaS(O)2-, -OC(O)O- o -O(CH2CH2O)n- donde n es un número entero entre 1 y 6, y Ra y Rb representan independientemente hidrógeno o alquilo (C1-3); R9 representa alquilo (C1-6), grupo olefínico (C2-6), grupo hidrocarburos cíclicos (C3-6), heterociclilo, alquinilo (C2-6), alquil(C1-6)-hidrocarburo cíclico(C3-6) o alquil(C1-6)-heterociclilo, y donde R9 puede ser opcionalmente sustituido con uno o más sustituyentes representados por R10; R10 representa halógeno, hidroxi, mercapto, trifluorometilo, amino, alquilo (C1-6), alcoxi (C1-6), alquiltio (C1-6), alquilamino (C1-6) o alcoxicarbonilo (C1-6); y las sales, solvatos e hidratos farmacéuticamente aceptables de los mismos.
ARP030104756A 2002-12-20 2003-12-19 Compuestos de aminobenzofenona AR042634A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43479802P 2002-12-20 2002-12-20

Publications (1)

Publication Number Publication Date
AR042634A1 true AR042634A1 (es) 2005-06-29

Family

ID=32682109

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104756A AR042634A1 (es) 2002-12-20 2003-12-19 Compuestos de aminobenzofenona

Country Status (16)

Country Link
US (1) US20060058380A1 (es)
EP (1) EP1583735A2 (es)
JP (1) JP2006510688A (es)
KR (1) KR20050089056A (es)
CN (1) CN1753861A (es)
AR (1) AR042634A1 (es)
AU (1) AU2003287917A1 (es)
BR (1) BR0317445A (es)
CA (1) CA2510711A1 (es)
IS (1) IS7943A (es)
MX (1) MXPA05006435A (es)
NO (1) NO20053562L (es)
PL (1) PL377377A1 (es)
RU (1) RU2005122951A (es)
WO (1) WO2004056762A2 (es)
ZA (1) ZA200504720B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014672A (es) * 2004-06-28 2007-03-26 Incyte Corp 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas.
WO2006004741A2 (en) * 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MX2007006739A (es) 2004-12-13 2007-08-02 Leo Pharma As Compuestos de aminobenzofenona sustituidos con triazol.
WO2019037791A1 (zh) * 2017-08-25 2019-02-28 广州市恒诺康医药科技有限公司 一种长效雷沙吉兰前药及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1535401A (en) * 1977-07-28 1978-12-13 Holliday & Co Ltd L Nitrodiphenylamine carboxylic acid disperse dyes
GB9701453D0 (en) * 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
US6897236B1 (en) * 1999-07-16 2005-05-24 Leo Pharmaceutical Products, Ltd. Aminobenzophenones as inhibitors of IL-1β and TNF-α
ATE277897T1 (de) * 1999-07-16 2004-10-15 Leo Pharma As Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
CZ200283A3 (cs) * 1999-07-16 2002-06-12 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemis Aminobenzofenony jako inhibitory IL-1beta a TNF-alfa
ATE362912T1 (de) * 1999-12-06 2007-06-15 Leo Pharma As Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
US20020165286A1 (en) * 2000-12-08 2002-11-07 Hanne Hedeman Dermal anti-inflammatory composition
AU2002338286A1 (en) * 2001-04-10 2002-10-28 Leo Pharma A/S Novel aminophenyl ketone derivatives
CN100347151C (zh) * 2001-08-28 2007-11-07 利奥制药有限公司 新的氨基苯酰苯类化合物

Also Published As

Publication number Publication date
WO2004056762A3 (en) 2004-08-12
NO20053562L (no) 2005-07-20
EP1583735A2 (en) 2005-10-12
WO2004056762A2 (en) 2004-07-08
BR0317445A (pt) 2005-11-16
AU2003287917A1 (en) 2004-07-14
US20060058380A1 (en) 2006-03-16
PL377377A1 (pl) 2006-02-06
ZA200504720B (en) 2006-08-30
MXPA05006435A (es) 2005-09-08
CA2510711A1 (en) 2004-07-08
RU2005122951A (ru) 2006-01-27
CN1753861A (zh) 2006-03-29
IS7943A (is) 2005-07-18
JP2006510688A (ja) 2006-03-30
KR20050089056A (ko) 2005-09-07

Similar Documents

Publication Publication Date Title
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
AR086086A1 (es) Derivados glucosidos y usos de los mismos
UY26727A1 (es) Derivados de tropano útiles en terapia
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR039150A1 (es) Piridinoilpiperidinas como agonistas de 5-ht1f
AR048362A1 (es) Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
PE20030129A1 (es) Imidazotriazinas
AR052580A1 (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR038419A1 (es) Derivados de piridina y quinolina
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
PE20130399A1 (es) COMPUESTOS DE NUCLEO IMIDAZO[1,2-a]PIRAZINA O 5,6,7,8-TETRAHIDROIMIDAZO[1,2-a]PIRAZINA SUSTITUIDOS Y COMPOSICIONES DE LOS MISMOS, UTILES EN EL TRATAMIENTO DE ENFERMEDADES PARASITICAS
AR043673A1 (es) Compuestos heterociclicos inhibidores no nucleosidos de la transcriptasa inversa i, preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del sida
UY29204A1 (es) Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados
AR048876A1 (es) Un proceso para preparar montelukast y compuestos intermedios para el mismo
AR068367A1 (es) Derivados de amidas con actividad fungicida
PA8810101A1 (es) Derivados de imidazo[1,2-a]piridin-2-carboxamidas, su preparación y su aplicación en terapéutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure